11/27/2012

Direct-to-consumer campaigns for three aromatase inhibitors did not spur more prescriptions for premenopausal breast cancer patients but may have increased prescriptions for postmenopausal patients, for whom the drugs are indicated, a study published in the journal Cancer found.

Related Summaries